Paul Griffiths, Dominique Lopez, Roumen Sedefov, Ana Gallegos, Brendan Hughes, André Noor, Luis Royuela
07 မေလ 2010
The aim of the study was to review the information available on the use of khat (Catha edulis) in the EU, and to assess the future use of this drug and related substances. Khat use sits awkwardly within the current EU reporting framework, and this hampers the production of a European-level analysis of the use of this drug. Why this is so, and what information is available at the European level, are the topics addressed in this paper. The analysis is extended to consider if the current evidence suggests that this drug, or synthetic variations of the psychoactive compounds it contains, are likely to play a greater role in the European drug scene of the future.
Within the last decade the hitherto little known psychoactive substance of khat has emerged as a regional and international issue. In the Horn of Africa khat production has spurred an economic boom, but dramatic increases in consumption have raised public health concerns. Given the complexity of the topic spanning multiple academic disciplines and fields of professional practice, the need for a systematic overview is urgent.